JP2004523557A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004523557A5 JP2004523557A5 JP2002567298A JP2002567298A JP2004523557A5 JP 2004523557 A5 JP2004523557 A5 JP 2004523557A5 JP 2002567298 A JP2002567298 A JP 2002567298A JP 2002567298 A JP2002567298 A JP 2002567298A JP 2004523557 A5 JP2004523557 A5 JP 2004523557A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharmaceutical composition
- composition according
- alkyl
- pyrrolidone compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 36
- -1 pyrrolidone compound Chemical class 0.000 claims 23
- 208000016686 tic disease Diseases 0.000 claims 15
- 230000003252 repetitive effect Effects 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 208000013403 hyperactivity Diseases 0.000 claims 10
- 150000002431 hydrogen Chemical group 0.000 claims 9
- 206010044565 Tremor Diseases 0.000 claims 8
- 125000004103 aminoalkyl group Chemical group 0.000 claims 7
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 7
- 125000000547 substituted alkyl group Chemical group 0.000 claims 7
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 7
- 238000011282 treatment Methods 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 208000000323 Tourette Syndrome Diseases 0.000 claims 5
- 208000016620 Tourette disease Diseases 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 238000011321 prophylaxis Methods 0.000 claims 5
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims 4
- 229960004002 levetiracetam Drugs 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229960004526 piracetam Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000001660 hyperkinetic effect Effects 0.000 claims 2
- 229960003389 pramiracetam Drugs 0.000 claims 2
- ZULJGOSFKWFVRX-UHFFFAOYSA-N pramiracetam Chemical compound CC(C)N(C(C)C)CCNC(=O)CN1CCCC1=O ZULJGOSFKWFVRX-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000015879 Cerebellar disease Diseases 0.000 claims 1
- 206010016212 Familial tremor Diseases 0.000 claims 1
- 206010022520 Intention tremor Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 206010071390 Resting tremor Diseases 0.000 claims 1
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 229960000793 aniracetam Drugs 0.000 claims 1
- ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000006517 essential tremor Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- LCAFGJGYCUMTGS-UHFFFAOYSA-N nebracetam Chemical compound O=C1CC(CN)CN1CC1=CC=CC=C1 LCAFGJGYCUMTGS-UHFFFAOYSA-N 0.000 claims 1
- 229950010963 nebracetam Drugs 0.000 claims 1
- NGHTXZCKLWZPGK-UHFFFAOYSA-N nefiracetam Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1C(=O)CCC1 NGHTXZCKLWZPGK-UHFFFAOYSA-N 0.000 claims 1
- 229950004663 nefiracetam Drugs 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 229960001227 oxiracetam Drugs 0.000 claims 1
- IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 claims 1
- 150000004040 pyrrolidinones Chemical class 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27098701P | 2001-02-23 | 2001-02-23 | |
| PCT/US2002/005189 WO2002067931A1 (en) | 2001-02-23 | 2002-02-22 | Treatment of tics, tremors and related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004523557A JP2004523557A (ja) | 2004-08-05 |
| JP2004523557A5 true JP2004523557A5 (enExample) | 2005-12-22 |
Family
ID=23033711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002567298A Pending JP2004523557A (ja) | 2001-02-23 | 2002-02-22 | チック、振せん、および関連疾患の治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040116505A1 (enExample) |
| EP (1) | EP1379236A4 (enExample) |
| JP (1) | JP2004523557A (enExample) |
| AU (1) | AU2002245486B2 (enExample) |
| CA (1) | CA2438930A1 (enExample) |
| WO (1) | WO2002067931A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2461961A1 (en) * | 2001-10-08 | 2003-04-17 | Ucb, S.A. | Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders |
| US7427601B2 (en) * | 2004-06-24 | 2008-09-23 | Schwarz Pharma Ag | Method for treating tremor |
| US20070259859A1 (en) * | 2006-05-04 | 2007-11-08 | De Bruin Natasja M W J | Muscarinic agonists to treat impulse control disorders |
| ES2336275T3 (es) * | 2006-05-04 | 2010-04-09 | Solvay Pharmaceuticals B.V. | Agonistas muscarinicos para tratar trastornos del control de impulsos. |
| BRPI0920342A2 (pt) * | 2008-10-16 | 2020-06-23 | The Johns Hopkins University | Uso de um inibidor da proteína vesicular sináptica 2a (sv2a) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica para melhora da função cognitiva, uso de levitiracetam ou um sal farmaceuticamente aceitável do mesmo, uso de brivaracetam ou um sal farmaceuticamente aceitável do mesmo, uso do seletracetam ou um sal farmaceuticamente aceitável do mesmo |
| EP2533645B1 (en) * | 2010-02-09 | 2016-07-27 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| AU2011293363A1 (en) | 2010-08-24 | 2013-02-28 | The Children's Hospital Of Philadelphia | Association of rare recurrent genetic variations to attention-deficit, hyperactivity disorder (ADHD) and methods of use thereof for the diagnosis and treatment of the same |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| CN103044307A (zh) * | 2013-01-24 | 2013-04-17 | 吉林三善恩科技开发有限公司 | 以2,4-二羟基苯甲酸为前驱体的吡拉西坦药物共晶及其制备方法 |
| CN103073477A (zh) * | 2013-01-24 | 2013-05-01 | 吉林三善恩科技开发有限公司 | 以3,4-二羟基苯甲酸为前驱体的吡拉西坦药物共晶及其制备方法 |
| EP2968237A4 (en) | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
| CN105142623A (zh) | 2013-03-15 | 2015-12-09 | 艾吉因生物股份有限公司 | 用于改善认知功能的方法和组合物 |
| US11219617B2 (en) | 2014-05-30 | 2022-01-11 | The Children's Hospital Of Philadelphia | Methods of diagnosing and treating autism |
| JP6766036B2 (ja) * | 2014-06-02 | 2020-10-07 | ケトゲン インコーポレイテッド | 発作および他の中枢神経系障害および状態の処置のための化合物 |
| CN107810002B (zh) | 2015-05-22 | 2021-01-05 | 艾吉因生物股份有限公司 | 左乙拉西坦的延时释放药物组合物 |
| AU2016318786B2 (en) | 2015-09-08 | 2022-04-07 | The Children's Hospital Of Philadelphia | Methods of diagnosing and treating anxiety disorder |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4355027A (en) * | 1977-11-02 | 1982-10-19 | Massachusetts Institute Of Technology | Process and composition for treating disorders by administering piracetam and choline |
| CH657527A5 (de) * | 1980-02-13 | 1986-09-15 | Ciba Geigy Ag | Verwendung von zentralnervoes-wirksamen verbindungen in einem mittel, welches zur verhinderung oder linderung von nebenwirkungen bestimmt ist. |
| GB8412357D0 (en) * | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| JPH0829140B2 (ja) * | 1987-04-17 | 1996-03-27 | 開成工業株式会社 | 末▲梢▼循環機能障害診断用皮フ温測定装置 |
| US6107492A (en) * | 1998-05-08 | 2000-08-22 | Ucb, S.A. | Process for the preparation of levetiracetam |
| TWI238062B (en) * | 1999-12-01 | 2005-08-21 | Ucb Sa | A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorders |
| GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
-
2002
- 2002-02-22 EP EP02713649A patent/EP1379236A4/en not_active Withdrawn
- 2002-02-22 AU AU2002245486A patent/AU2002245486B2/en not_active Ceased
- 2002-02-22 WO PCT/US2002/005189 patent/WO2002067931A1/en not_active Ceased
- 2002-02-22 US US10/468,937 patent/US20040116505A1/en not_active Abandoned
- 2002-02-22 CA CA002438930A patent/CA2438930A1/en not_active Abandoned
- 2002-02-22 JP JP2002567298A patent/JP2004523557A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004523557A5 (enExample) | ||
| JP5667684B2 (ja) | 関節炎の治療方法 | |
| RU2006116887A (ru) | Производные n-[гетероарил(пиперидин-2-ил)метил]бензамида, способ получения указанных соединений и их применение в терапии | |
| RU94044671A (ru) | Применение непептидных антагонистов рецептора тахикинина | |
| EA200801165A1 (ru) | Антагонисты неосновного рецептора-1 меланинконцентрирующего гормона | |
| JP2005506352A5 (enExample) | ||
| CA2528160A1 (en) | Use of 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine for neuronal regeneration and functional recovery | |
| TW200621249A (en) | Substituted amide beta secretase inhibitors | |
| HUP0204526A2 (hu) | 2-Oxo-1-pirrolidin-származékok, eljárás előállításukra és alkalmazásuk | |
| TW200607807A (en) | Macrocyclic beta-secretase inhibitors | |
| CN102387704A (zh) | S1p5受体的激动剂和拮抗剂，和其用法 | |
| JP2006507220A5 (enExample) | ||
| JP2006503850A5 (enExample) | ||
| US20040116505A1 (en) | Treatment of tics, tremors and related disorders | |
| RU2007128085A (ru) | Соли четвертичного аммония в качестве антагонистов м3 | |
| AU2002245486A1 (en) | Treatment of tics, tremors and related disorders | |
| JP2008538583A5 (enExample) | ||
| RU2006138495A (ru) | Использование агонистов рецепторов, активируемых пролифератором пероксисомы дельта для лечения рс и других демиелинизирующих заболеваний | |
| TNSN05246A1 (en) | Use of 10-hydroxy-10, 11-dihydrocarbamazepine derivatives for the treatment of affective disorders | |
| JPH06500099A (ja) | Ｃｎｓ疾病の処置におけるヘテロ環状アミノ―アルコール化合物の使用 | |
| RU2007128080A (ru) | Производные пирролидиния в качестве мускариновых рецепторов мз | |
| EP1201240A3 (en) | Heterocyclic derivatives useful as pharmaceutical agents | |
| CA2534634A1 (en) | Azolidinecarbonitriles and their use as dpp-iv inhibitors | |
| JP2006510659A5 (enExample) | ||
| JP2005501108A (ja) | 神経変性治療におけるネフィラセタムの使用 |